IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
@Olie_Mac @alxbenevides @t_batyraliev @KrishKancharla @rafmatcom @drrajinder1984 @psmedic @SamiUllahShaki2 @GiladJaffe
@BaoGTran @AntoniousAttall @DrNayef1 @Bernard_TW_Wong @RAAnderson1 @DrNayef1 @DrPeterOKane @Babar_Basir… https://t.co/IYKNthJApw
Thank you for your thoughts & discussion on this publication over the last few days - it's important for physicians… https://t.co/DAuWcnGlVQ
Hear perspective from #ShockwaveIVL CMO Dr. Keith Dawkins on the first reported case of ventricular fibrillation (V… https://t.co/xU3e5ibBL0
Attend a live discussion on the impact of #DISRUPTCAD3 data on clinical practice with leading experts Drs.… https://t.co/Ep37k87w3U
Curious how #ShockwaveIVL performs in eccentric vs. concentric coronary calcifications? Drs. @mbmcentegart,… https://t.co/PL4qSbqkqe
Explore #ShockwaveIVL cases and the latest peripheral calcium data with Drs. Huasen, Thulasidasan & Lakshminarayan… https://t.co/p0TRrxLF5N
What a world of difference. Beautiful stand-alone #ShockwaveIVL case by Dr. Stanley Zimmerman at Hillcrest Medical… https://t.co/eXLBvsPTcX
Eccentric calcium has always been a pain…a real thorn in the interventionalists’ side. Hear how Drs @mbmcentegart… https://t.co/NKcyskCpIU
Learn more about #ShockwaveIVL as a solution to treat severe peripheral calcification at the #BSIRASM2020 online sy… https://t.co/ds6CqrlrOr
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
